REFERENCES
1. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res 2023;51:3000605231164548.
2. Freeman AM, Acevedo LA, Pennings N. Insulin resistance. StatPearls; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507839/ [Last accessed on 19 Oct 2024].
3. Brown AE, Walker M. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep 2016;18:75.
5. Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes 2015;64:673-86.
7. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-45.
8. Cai X, Sun J, Jin A, et al. Association of insulin resistance with intra- and extra-cranial atherosclerotic burden in the nondiabetic community population. Neurobiol Dis 2023;186:106268.
9. Min J, Weitian Z, Peng C, et al. Correlation between insulin-induced estrogen receptor methylation and atherosclerosis. Cardiovasc Diabetol 2016;15:156.
10. Barale C, Russo I. Influence of cardiometabolic risk factors on platelet function. Int J Mol Sci 2020;21:623.
11. da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol 2020;36:671-82.
12. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-46.
14. Šebeková K, Gurecká R, Csongová M, Koborová I, Repiská G, Podracká Ľ. Lean insulin-resistant young adults display increased cardiometabolic risk: a retrospective cross-sectional study. Diabetes Res Clin Pract 2022;185:109217.
15. Stewart AJ, Tuncay E, Pitt SJ, Rainbow RD. Editorial: insulin resistance and cardiovascular disease. Front Endocrinol 2023;14:1266173.
16. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res 2017;183:57-70.
17. Huang K, Shen R, Chen Q, et al. Insulin product decreases risk of varicose vein: evidence from a mendelian randomization study. Vasc Investig Ther 2021;4:75-82.
18. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 2022;46:15-37.
19. Angelidi AM, Filippaios A, Mantzoros CS. Severe insulin resistance syndromes. J Clin Invest 2021;131:142245.
21. Tahapary DL, Pratisthita LB, Fitri NA, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and tryglyceride/glucose index. Diabetes Metab Syndr 2022;16:102581.
22. Bermudez V, Salazar J, Martínez MS, et al. Prevalence and associated factors of insulin resistance in adults from maracaibo city, venezuela. Adv Prev Med 2016;2016:9405105.
23. Fahed M, Abou Jaoudeh MG, Merhi S, et al. Evaluation of risk factors for insulin resistance: a cross sectional study among employees at a private university in Lebanon. BMC Endocr Disord 2020;20:85.
24. Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc 2019;3:1727-47.
25. Alvarez S, Coffey R, Mathias PM, Algotar AM. Prediabetes. StatPearls; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459332/ [Last accessed on 19 Oct 2024].
26. Center for Disease Control and Prevention. National diabetes statistics report. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html [Last accessed on 19 Oct 2024].
27. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.
28. Holst JJ, Gasbjerg LS, Rosenkilde MM. The role of incretins on insulin function and glucose homeostasis. Endocrinology 2021;162:bqab065.
30. Bouskila M, Hirshman MF, Jensen J, Goodyear LJ, Sakamoto K. Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle. Am J Physiol Endocrinol Metab 2008;294:E28-35.
31. Sancar G, Liu S, Gasser E, et al. FGF1 and insulin control lipolysis by convergent pathways. Cell Metab 2022;34:171-83.e6.
32. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 2018;19:31-44.
33. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med 2016;48:e219.
34. Flores-Viveros KL, Aguilar-Galarza BA, Ordóñez-Sánchez ML, et al. Contribution of genetic, biochemical and environmental factors on insulin resistance and obesity in Mexican young adults. Obes Res Clin Pract 2019;13:533-40.
35. Guo CA, Guo S. Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure. J Endocrinol 2017;233:R131-43.
36. Wang J, Xu J. Effects of topical insulin on wound healing: a review of animal and human evidences. Diabetes Metab Syndr Obes 2020;13:719-27.
37. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
38. Dodd GT, Tiganis T. Insulin action in the brain: roles in energy and glucose homeostasis. J Neuroendocrinol 2017;29:e12513.
39. Salt IP. Examining the role of insulin in the regulation of cardiovascular health. Future Cardiol 2013;9:39-52.
40. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 2020;130:1453-60.
42. Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev 2019;40:1447-67.
43. Van Schouwenburg IM, Mahmoodi BK, Veeger NJ, et al. Insulin resistance and risk of venous thromboembolism: results of a population-based cohort study. J Thromb Haemost 2012;10:1012-8.
44. Vayá A, Martínez-Triguero ML, España F, Todolí JA, Bonet E, Corella D. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population. Metab Syndr Relat Disord 2011;9:197-201.
45. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2018;61:21-8.
46. Sędzikowska A, Szablewski L. Insulin and insulin resistance in Alzheimer's disease. Int J Mol Sci 2021;22:9987.
47. Ayromlou H, Hosseini S, Khalili M, et al. Insulin resistance is associated with cognitive dysfunction in multiple sclerosis patients: a cross-sectional study. J Neuroendocrinol 2023;35:e13288.
48. Kim HK, Song J. Hypothyroidism and diabetes-related dementia: focused on neuronal dysfunction, insulin resistance, and dyslipidemia. Int J Mol Sci 2022;23:2982.
49. Faiq MA, Sengupta T, Nath M, et al. Ocular manifestations of central insulin resistance. Neural Regen Res 2023;18:1139-46.
50. Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 2020;2020:3920196.
51. Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol 2021;2021:6613827.
52. Giles JT, Danielides S, Szklo M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol 2015;67:626-36.
53. Diaz-Rubio GI, Corona-Meraz FI, Madrigal-Ruiz PM, et al. CCR2/CCL2 and CMKLR1/RvE1 chemokines system levels are associated with insulin resistance in rheumatoid arthritis. PLoS One 2021;16:e0246054.
54. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res 2023;16:9.
55. Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer 2012;19:R225-41.
56. Toledo FGS, Chari S, Yadav D. Understanding the contribution of insulin resistance to the risk of pancreatic cancer. Am J Gastroenterol 2021;116:669-70.
57. Pierre N, Appriou Z, Gratas-Delamarche A, Derbré F. From physical inactivity to immobilization: dissecting the role of oxidative stress in skeletal muscle insulin resistance and atrophy. Free Radic Biol Med 2016;98:197-207.
58. Racette SB, Evans EM, Weiss EP, Hagberg JM, Holloszy JO. Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 year olds. Diabetes Care 2006;29:673-8.
59. De Paoli M, Zakharia A, Werstuck GH. The role of estrogen in insulin resistance: a review of clinical and preclinical data. Am J Pathol 2021;191:1490-8.
60. Andrade MIS, Oliveira JS, Leal VS, et al. Prevalence of insulin resistance and association with metabolic risk factors and food consumption in adolescents - Recife/Brazil. Rev Paul Pediatr 2020;38:e2019016.
61. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, Qiao Q. DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010;33:2211-6.
62. Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am 2013;97:791-805.
63. Boudreau DM, Malone DC, Raebel MA, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord 2009;7:305-14.
64. Nichols GA, Amitay EL, Chatterjee S, Steubl D. Health care costs associated with the development and combination of cardio-renal-metabolic diseases. Kidney360 2023;4:1382-8.
65. Eklof B, Perrin M, Delis KT, et al. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009;49:498-501.
66. Lurie F, Passman M, Meisner M, et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord 2020;8:342-52.
67. Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg 2021;274:971-6.
68. MacColl E, Khalil RA. Matrix metalloproteinases as regulators of vein structure and function: implications in chronic venous disease. J Pharmacol Exp Ther 2015;355:410-28.
69. De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor’s choice - European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg 2022;63:184-267.
70. Recek C. Conception of the venous hemodynamics in the lower extremity. Angiology 2006;57:556-63.
71. Townsley MI. Structure and composition of pulmonary arteries, capillaries, and veins. In: Comprehensive physiology. Wiley; 2011. pp. 675-709.
72. Urbanek T, Skop B, Wiaderkiewicz R, et al. Smooth muscle cell apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg 2004;28:600-11.
74. Ortega MA, Fraile-Martínez O, García-Montero C, et al. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med 2021;10:3239.
75. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005;15:175-84.
76. Jarošíková R, Roztočil K, Husáková J, et al. Chronic venous disease and its intersections with diabetes mellitus. Physiol Res 2023;72:280-6.
77. Gastaldi G, Pannier F, Roztočil K, et al. Chronic venous disease and diabetic microangiopathy: pathophysiology and commonalities. Int Angiol 2021;40:457-69.
78. Chung WS, Lin CL, Kao CH. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study. Thromb Haemost 2015;114:812-8.
79. Fiebig A, Krusche P, Wolf A, et al. Heritability of chronic venous disease. Hum Genet 2010;127:669-74.
80. Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol 2017;960:277-304.
81. Li X, Yang Y, Shi X, Zhang Z, Ding S. Mitochondria-associated membranes as key regulators in cellular homeostasis and the potential impact of exercise on insulin resistance. Int J Mol Sci 2024;25:3196.
82. Dong Z, Yao X. Insight of the role of mitochondrial calcium homeostasis in hepatic insulin resistance. Mitochondrion 2022;62:128-38.
83. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64.
84. Onyango AN. Cellular stresses and stress responses in the pathogenesis of insulin resistance. Oxid Med Cell Longev 2018;2018:4321714.
85. Rzheshevsky AV. Decrease in ATP biosynthesis and dysfunction of biological membranes. Two possible key mechanisms of phenoptosis. Biochemistry 2014;79:1056-68.
86. Ayer A, Fazakerley DJ, James DE, Stocker R. The role of mitochondrial reactive oxygen species in insulin resistance. Free Radic Biol Med 2022;179:339-62.
87. Smetanina MA, Oscorbin IP, Shadrina AS, et al. Quantitative and structural characteristics of mitochondrial DNA in varicose veins. Vascul Pharmacol 2022;145:107021.
88. Smetanina MA, Kel AE, Sevost’ianova KS, et al. DNA methylation and gene expression profiling reveal MFAP5 as a regulatory driver of extracellular matrix remodeling in varicose vein disease. Epigenomics 2018;10:1103-19.
89. Rötig A, Parfait B, Heidet L, Dujardin G, Rustin P, Munnich A. Sequence and structure of the human OXA1L gene and its upstream elements. Biochim Biophys Acta 1997;1361:6-10.
90. Poerschke S, Oeljeklaus S, Cruz-Zaragoza LD, et al. Identification of TMEM126A as OXA1L-interacting protein reveals cotranslational quality control in mitochondria. Mol Cell 2024;84:345-58.e5.
91. Xu Y, Bei Y, Li Y, Chu H. Phenotypic and functional transformation in smooth muscle cells derived from varicose veins. J Vasc Surg Venous Lymphat Disord 2017;5:723-33.
92. Ugarte-Uribe B, García-Sáez AJ. Apoptotic foci at mitochondria: in and around Bax pores. Philos Trans R Soc Lond B Biol Sci 2017;372:20160217.
93. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995;1271:63-6.
94. Gong Y, Luo S, Fan P, Zhu H, Li Y, Huang W. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. Reprod Biol Endocrinol 2020;18:121.
95. Lim CS, Kiriakidis S, Paleolog EM, Davies AH. Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg 2012;55:1427-39.
96. Vande Velde C, Cizeau J, Dubik D, et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000;20:5454-68.
97. Shadrina AS, Sharapov SZ, Shashkova TI, Tsepilov YA. Varicose veins of lower extremities: insights from the first large-scale genetic study. PLoS Genet 2019;15:e1008110.
98. Jiang M, Zhang YX, Bu WJ, et al. Piezo1 channel activation stimulates ATP production through enhancing mitochondrial respiration and glycolysis in vascular endothelial cells. Br J Pharmacol 2023;180:1862-77.
99. Zhao C, Sun Q, Tang L, et al. Mechanosensitive ion channel piezo1 regulates diet-induced adipose inflammation and systemic insulin resistance. Front Endocrinol 2019;10:373.
100. Pfluger PT, Kabra DG, Aichler M, et al. Calcineurin links mitochondrial elongation with energy metabolism. Cell Metab 2015;22:838-50.
101. Li M, Gong W, Chen J, Zhang Y, Ma Y, Tu X. PPP3R1 promotes MSCs senescence by inducing plasma membrane depolarization and increasing Ca2+ influx. Int J Mol Sci 2023;24:4421.
102. Zhou Z, Bai J, Zhong S, et al. Integrative genomic analysis of PPP3R1 in Alzheimer’s disease: a potential biomarker for predictive, preventive, and personalized medical approach. EPMA J 2021;12:647-58.
103. Brandman O, Liou J, Park WS, Meyer T. STIM2 is a feedback regulator that stabilizes basal cytosolic and endoplasmic reticulum Ca2+ levels. Cell 2007;131:1327-39.
104. O’Day DH. Calmodulin binding proteins and alzheimer's disease: biomarkers, regulatory enzymes and receptors that are regulated by calmodulin. Int J Mol Sci 2020;21:7344.
105. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635-45.
106. Asghar A, Sheikh N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell Immunol 2017;315:18-26.
107. Klimczak S, Śliwińska A. Epigenetic regulation of inflammation in insulin resistance. Semin Cell Dev Biol 2024;154:185-92.
108. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
110. Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002;87:2084-9.
111. Curat CA, Miranville A, Sengenès C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004;53:1285-92.
112. Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth Factor Rev 2018;44:38-50.
113. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-84.
114. Groeger M, Matsuo K, Heidary Arash E, et al. Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages. Nat Commun 2023;14:3902.
115. Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2018;119:105-10.
116. Kim TH, Choi SE, Ha ES, et al. IL-6 induction of TLR-4 gene expression via STAT3 has an effect on insulin resistance in human skeletal muscle. Acta Diabetol 2013;50:189-200.
117. Kim JH, Kim JE, Liu HY, Cao W, Chen J. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008;283:708-15.
118. Reardon CA, Lingaraju A, Schoenfelt KQ, et al. Obesity and insulin resistance promote atherosclerosis through an IFNγ-regulated macrophage protein network. Cell Rep 2018;23:3021-30.
119. Jacobs BN, Andraska EA, Obi AT, Wakefield TW. Pathophysiology of varicose veins. J Vasc Surg Venous Lymphat Disord 2017;5:460-7.
120. Tisato V, Zauli G, Voltan R, et al. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7:e39543.
121. Abd El-Kader SM, Al-Jiffri OH. Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients. Afr Health Sci 2018;18:873-83.
122. Mikuła-Pietrasik J, Uruski P, Aniukiewicz K, et al. Serum from Varicose patients induces senescence-related dysfunction of vascular endothelium generating local and systemic proinflammatory conditions. Oxid Med Cell Longev 2016;2016:2069290.
123. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000;32 Suppl 1:78-84.
124. Bui TM, Wiesolek HL, Sumagin R. ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol 2020;108:787-99.
125. Tuleta I, Frangogiannis NG. Diabetic fibrosis. Biochim Biophys Acta Mol Basis Dis 2021;1867:166044.
126. Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J. Are inflammatory biomarkers increased in varicose vein blood? Clin Appl Thromb Hemost 2016;22:656-64.
127. Smetanina MA, Shevela AI, Gavrilov KA, Filipenko ML. The genetic constituent of varicose vein pathogenesis as a key for future treatment option development. Vessel Plus 2021;5:19.
128. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011;60:1512-8.
129. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005;22 Suppl 2:3-10.
130. Singh A, Babyak MA, Nolan DK, et al. Gene by stress genome-wide interaction analysis and path analysis identify EBF1 as a cardiovascular and metabolic risk gene. Eur J Hum Genet 2015;23:854-62.
131. Gustafson B, Smith U. Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. J Biol Chem 2010;285:14031-41.
132. Lin HY, Weng SW, Shen FC, et al. Abrogation of toll-like receptor 4 mitigates obesity-induced oxidative stress, proinflammation, and insulin resistance through metabolic reprogramming of mitochondria in adipose tissue. Antioxid Redox Signal 2020;33:66-86.
133. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci 2013;9:1057-69.
134. Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009;52:752-64.
135. Bradley EA, Richards SM, Keske MA, Rattigan S. Local NOS inhibition impairs vascular and metabolic actions of insulin in rat hindleg muscle in vivo. Am J Physiol Endocrinol Metab 2013;305:E745-50.
136. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007;75:247-60.
137. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463-91.
138. Liu Y, Petreaca M, Martins-Green M. Cell and molecular mechanisms of insulin-induced angiogenesis. J Cell Mol Med 2009;13:4492-504.
139. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:402-9.
140. Tiwari S, Sharma N, Gill PS, et al. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci USA 2008;105:6469-74.
141. Bindlish S, Ng J, Ghusn W, Fitch A, Bays HE. Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: an obesity medicine association (OMA) clinical practice statement (CPS) 2023. Obes Pillars 2023;8:100092.
143. Segiet OA, Brzozowa-Zasada M, Piecuch A, Dudek D, Reichman-Warmusz E, Wojnicz R. Biomolecular mechanisms in varicose veins development. Ann Vasc Surg 2015;29:377-84.
144. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:6184-223.
145. Costa D, Andreucci M, Ielapi N, et al. Molecular determinants of chronic venous disease: a comprehensive review. Int J Mol Sci 2023;24:1928.
146. Smetanina MA, Korolenya VA, Kel AE, et al. Epigenome-wide changes in the cell layers of the vein wall when exposing the venous endothelium to oscillatory shear stress. Epigenomes 2023;7:8.
147. Laakkonen JP, Lähteenvuo J, Jauhiainen S, Heikura T, Ylä-Herttuala S. Beyond endothelial cells: vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul Pharmacol 2019;112:91-101.
148. Birdina J, Pilmane M, Ligers A. The morphofunctional changes in the wall of varicose veins. Ann Vasc Surg 2017;42:274-84.
149. Sun X, Zhang H, Liu J, Wang G. Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Int Med Res 2019;47:5584-92.
150. Kowalewski R, Małkowski A, Sobolewski K, Gacko M. Vascular endothelial growth factor and its receptors in the varicose vein wall. Acta Angiol 2011;17:144-9. Available from: https://journals.viamedica.pl/acta_angiologica/article/view/18677 [Last accessed on 19 Oct 2024]
151. Bruczko-Goralewska M, Romanowicz L, Bączyk J, Wolańska M, Sobolewski K, Kowalewski R. Peptide growth factors and their receptors in the vein wall. J Investig Med 2019;67:1149-54.
152. van der Stoel MM, Kotini MP, Schoon RM, Affolter M, Belting HG, Huveneers S. Vinculin strengthens the endothelial barrier during vascular development. Vasc Biol 2023;5:e220012.
153. Fukaya E, Flores AM, Lindholm D, et al. Clinical and genetic determinants of varicose veins. Circulation 2018;138:2869-80.
154. Shao J, Zeng S, Zhou B, Xu H, Bian Y, Xu Y. Angiogenic factor with G patch and FHA domains 1 (Aggf1) promotes hepatic steatosis in mice. Biochem Biophys Res Commun 2017;482:134-40.
155. D'Oria R, Laviola L, Giorgino F, Unfer V, Bettocchi S, Scioscia M. PKB/Akt and MAPK/ERK phosphorylation is highly induced by inositols: novel potential insights in endothelial dysfunction in preeclampsia. Pregnancy Hypertens 2017;10:107-12.
156. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999;42:246-53.
157. Kim JI, Huh JY, Sohn JH, et al. Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation. Mol Cell Biol 2015;35:1686-99.
158. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 2001;193:398-407.
159. Surendran S, Ramegowda KS, Suresh A, et al. Arterialization and anomalous vein wall remodeling in varicose veins is associated with upregulated FoxC2-Dll4 pathway. Lab Invest 2016;96:399-408.
160. Zhang X, Wang Y, Zuo F, et al. Effect of insulin-regulated FOXC2 expression in adipocyte differentiation and insulin resistance. Diabetes Metab Syndr Obes 2020;13:2801-9.
161. Meissburger B, Stachorski L, Röder E, Rudofsky G, Wolfrum C. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia 2011;54:1468-79.
162. Serralheiro P, Soares A, Costa Almeida CM, Verde I. TGF-β1 in vascular wall pathology: unraveling chronic venous insufficiency pathophysiology. Int J Mol Sci 2017;18:2534.
163. Asthana P, Wong HLX. Preventing obesity, insulin resistance and type 2 diabetes by targeting MT1-MMP. Biochim Biophys Acta Mol Basis Dis 2024;1870:167081.
164. Smetanina MA, Korolenya VA, Sipin FA, et al. Loci cg06256735 and cg15815843 in the MFAP5 gene regulatory regions are hypomethylated in varicose veins apparently due to active demethylation. Biosci Rep 2024;44:BSR20231938.
165. Combs MD, Knutsen RH, Broekelmann TJ, et al. Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo. J Biol Chem 2013;288:28869-80.
166. Chen Z, Zhao H, Meng L, Yu S, Liu Z, Xue J. Microfibril-associated glycoprotein-2 promoted fracture healing via integrin αvβ3/PTK2/AKT signaling. Lab Invest 2023;103:100121.
167. Lemaire R, Korn JH, Shipley JM, Lafyatis R. Increased expression of type I collagen induced by microfibril-associated glycoprotein 2: novel mechanistic insights into the molecular basis of dermal fibrosis in scleroderma. Arthritis Rheum 2005;52:1812-23.
168. Vaittinen M, Kolehmainen M, Schwab U, Uusitupa M, Pulkkinen L. Microfibrillar-associated protein 5 is linked with markers of obesity-related extracellular matrix remodeling and inflammation. Nutr Diabetes 2011;1:e15.
169. Özen G, Doğan BSU, Teskin Ö, Norel X, Topal G. The role of perivascular adipose tissue on human saphenous vein vascular tone. J Fac Pharm Istanbul 2016;46:1-13. Available from: https://dergipark.org.tr/tr/download/article-file/266733 [Last accessed on 19 Oct 2024]
